Know Cancer

forgot password

Presurgical Smoking Cessation Intervention for Cancer Patients: The Resolve Study

18 Years
Open (Enrolling)
Newly Diagnosed Cancer Patients

Thank you

Trial Information

Presurgical Smoking Cessation Intervention for Cancer Patients: The Resolve Study

Smoking cessation offers an important way for newly diagnosed cancer patients to take an
active role in their treatment and recovery. Quitting tobacco use decreases cancer patients'
risk of disease recurrence and development of second primary cancers. In addition,
preoperative tobacco cessation may reduce the likelihood of perioperative pulmonary,
cardiovascular, and wound healing complications. Due to increased awareness of the health
hazards of tobacco use, rates of cessation after cancer diagnosis are high. However, 35% to
69% of patients continue to use tobacco and this is largely due to strong barriers to
quitting (low-self efficacy, psychological distress) rather than lack of positive intentions
to quit. Previous attempts to increase smoking cessation among the medically ill have
provided intervention either during or after hospitalization.

We propose that the period immediately prior to hospitalization and surgery represents a
unique window of opportunity, or "teachable moment," for smoking cessation that could take
full advantage of patients' enhanced health awareness and quitting motivation, strong
physician quitting advice, and patients' heightened desire to take an active role in their

Inclusion Criteria:

- Age 18 years or older

- Smokers who typically smoke > 8 cigarettes per day who have smoked within the last 7
days or other tobacco users with high frequency of use (> 8 per day) within the last
7 days;

- Diagnosed with cancer or have a mass suspicious of cancer that is NOT distant
metastatic cancer at the time of enrollment;

- Likely candidate for surgical treatment no sooner than 7 days from study entry;

- Absence of gross psychopathology or cognitive impairment;

- Can be reached by telephone;

- Have manual dexterity and sensory (i.e., visual and auditory) acuity sufficient to
use a Personal Digital Assistant (PDA);

- Provide informed consent.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

efficacy of a presurgical smoking cessation intervention that adds scheduled reduced smoking, a highly effective behavioral treatment in non-medically ill tobacco users, to enhanced usual care, i.e., hospital counseling and nicotine replacement therapy.

Outcome Time Frame:

will be measured at hospital admission, and 3 and 6 months post-hospital admission.

Safety Issue:


Principal Investigator

Jamie Ostroff, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

October 2002

Completion Date:

October 2013

Related Keywords:

  • Newly Diagnosed Cancer Patients
  • Quitting tobacco
  • tobacco use



Memorial Sloan Kettering Cancer Center New York, New York  10021